Oncology Research

GeoVax Expands Gedeptin Cancer Therapy Development to Additional Solid Tumor Types

GeoVax Expands Gedeptin Cancer Therapy Development to Additional Solid Tumor Types

GeoVax Labs is expanding its Gedeptin cancer therapy development to include triple negative breast cancer and cutaneous malignancies, building on checkpoint inhibitor momentum and KEYNOTE-689 results to potentially improve outcomes for broader solid tumor patients.

September 24, 2025
CNS Pharmaceuticals CEO Outlines Glioblastoma Treatment Strategy and Market Opportunities in Podcast Interview

CNS Pharmaceuticals CEO Outlines Glioblastoma Treatment Strategy and Market Opportunities in Podcast Interview

CNS Pharmaceuticals CEO John Climaco discussed the company's progress in developing novel brain cancer treatments and expanding into aggressive cancers like triple-negative breast cancer with brain metastases during a recent BioMedWire podcast appearance.

August 27, 2025
Calidi Biotherapeutics' Genetic Medicine Platform Featured in Editorial for Cancer Treatment Innovation

Calidi Biotherapeutics' Genetic Medicine Platform Featured in Editorial for Cancer Treatment Innovation

Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been highlighted in an editorial for its precision genetic medicine platform, offering a novel approach to targeting cancer tumors amidst rising global diagnoses.

July 8, 2025
RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board

RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board

TransCode Therapeutics has appointed Dr. Phillip D. Zamore, a leading RNAi researcher, to its Scientific Advisory Board, potentially strengthening the company's oncology research capabilities and RNA therapeutic development strategies.

May 28, 2025
Calidi Biotherapeutics Advances Cancer Treatment Platform with Innovative Immunotherapy Approach

Calidi Biotherapeutics Advances Cancer Treatment Platform with Innovative Immunotherapy Approach

Calidi Biotherapeutics has developed a novel systemic antitumor virotherapy platform that delivers an IL15 superagonist directly into tumor microenvironments, potentially revolutionizing metastatic cancer treatment by boosting immune response while minimizing systemic toxicity.

April 28, 2025